Mounjaro vs Ozempic (2026): 7 Key Differences Compared

On this page

• [Short answer](#mounjaro-vs-ozempic-the-short-answer)
• [At a glance](#mounjaro-vs-ozempic-at-a-glance)
• [Seven key differences](#1-they-use-different-active-ingredients)
• [Questions to ask](#questions-to-ask-before-choosing)
• [Frequently asked questions](#frequently-asked-questions)
• [Bottom line](#bottom-line)
• [How we keep this page current](#how-we-keep-this-page-current)
• [Official sources](#official-sources)

Mounjaro vs Ozempic: the short answer

Mounjaro contains tirzepatide, which acts at GIP and GLP-1 receptors. Ozempic contains semaglutide, which acts at the GLP-1 receptor. Both labels cover once-weekly prescription injections used with diet and exercise for type 2 diabetes, but the approved populations and risk-reduction indications are not identical. Neither Mounjaro nor Ozempic is FDA-approved under those brand names for weight loss. [S1][S2]

The strongest direct comparison is SURPASS-2, a 40-week open-label phase 3 trial in 1,879 adults with inadequately controlled type 2 diabetes who were taking metformin. It compared tirzepatide 5, 10, and 15 mg with semaglutide 1 mg. That boundary matters: the trial did not compare tirzepatide with Ozempic's current 2 mg maximum dose, and an average trial result cannot identify the better medication for one person. [S1][S2][S3]

The practical answer depends on the treatment goal, current FDA indications, contraindications, tolerability, insurance rules, and the clinician's assessment. If cost is the immediate constraint, use the Mounjaro cost without insurance guide and Ozempic cost without insurance guide as separate verification starting points rather than treating list price as your expected bill.

Mounjaro vs Ozempic at a glance

1. They use different active ingredients

Mounjaro's active ingredient is tirzepatide. Its label describes it as an agonist at both the glucose-dependent insulinotropic polypeptide, or GIP, receptor and the glucagon-like peptide-1, or GLP-1, receptor. Ozempic's active ingredient is semaglutide, and its label describes it as a GLP-1 receptor agonist. [S1][S2]

Both products are once-weekly injections. That shared cadence can make them look interchangeable in a search result, but their active ingredients, labeled dose ranges, approved populations, and precautions are distinct. They should not be treated as generic substitutes, and this guide provides no conversion or switching instructions. [S1][S2]

For readers comparing brand boundaries, the adjacent Mounjaro versus Zepbound label-and-cost guide explains why a shared ingredient does not make two brand labels identical. The same principle applies to semaglutide brands, as outlined in the Ozempic versus Wegovy label-and-cost guide.

2. Their FDA-approved uses are not the same

Both labels include use with diet and exercise to improve glycemic control in type 2 diabetes, but their full indication sections differ. Mounjaro is labeled for adults and pediatric patients age 10 and older with type 2 diabetes. Ozempic's current label is for adults and includes glycemic control plus specified risk-reduction indications for major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and for sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. [S1][S2]

This is where many comparison pages blur separate products. Evidence from Zepbound or Wegovy should not be presented as though it changed the approved Mounjaro or Ozempic brand label. This guide therefore does not import obesity-trial percentages from those brands into the direct Mounjaro-versus-Ozempic comparison.

3. The head-to-head trial favored tirzepatide—but only against semaglutide 1 mg

SURPASS-2 is more useful than comparing separate trials because it randomized participants within one study. The 40-week trial enrolled 1,879 adults with inadequately controlled type 2 diabetes who were receiving metformin. Participants received tirzepatide 5, 10, or 15 mg, or semaglutide 1 mg. It was open-label. [S1][S3]

At week 40, mean A1C changes were -2.01, -2.24, and -2.30 percentage points with tirzepatide 5, 10, and 15 mg, compared with -1.86 percentage points with semaglutide 1 mg. Mean body-weight differences versus semaglutide favored the tirzepatide groups by 1.9, 3.6, and 5.5 kg. These are group averages from adults with type 2 diabetes on metformin, not individual forecasts and not evidence that either brand is approved for weight loss. [S1][S3]

The missing 2 mg comparison is not a minor footnote. Ozempic's current label lists 0.5, 1, and 2 mg as maintenance doses based on glycemic control, while SURPASS-2 used semaglutide 1 mg. Saying only “Mounjaro beat Ozempic” strips away a key trial boundary. The accurate statement is narrower: tirzepatide at the studied doses produced larger average reductions than semaglutide 1 mg in the specified 40-week type 2 diabetes population. [S1][S2][S3]

4. The available dose ranges differ

The Mounjaro adult label spans strengths from 2.5 mg through 15 mg. It states that 2.5 mg is used for initiation and is not intended for glycemic control, and it lists 15 mg once weekly as the adult maximum. The pediatric maximum in the current label is 10 mg once weekly. Ozempic's label uses 0.25 mg for initiation and lists 0.5, 1, or 2 mg as maintenance doses based on glycemic control. [S1][S2]

Before inferring monthly cost from a sticker price, verify the prescribed presentation, package dose count, pharmacy availability, plan approval, and billing unit.

5. Side effects overlap, but label details matter

Both current labels carry a boxed warning stating that the drug caused thyroid C-cell tumors in rodents and that it is unknown whether it causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans. [S1][S2]

Both labels list contraindications involving a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and serious hypersensitivity to the product or its components. Those boundaries require clinician review; a comparison article cannot screen someone for them. [S1][S2]

Common gastrointestinal adverse reactions overlap. Mounjaro's label lists nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain among reactions reported in at least 5% of treated patients. Ozempic's label lists nausea, vomiting, diarrhea, abdominal pain, and constipation among reactions reported in at least 5% of treated patients. Different wording or percentages across labels and studies should not be simplified into a claim that one drug is universally safer or easier to tolerate. [S1][S2]

The Mounjaro label contains a specific precaution about oral hormonal contraceptives after initiation and after dose escalation. Review that instruction and the complete current medication list with a clinician or pharmacist rather than making self-directed changes. [S1]

6. List prices and what your plan can change

As of August 2, 2026, Lilly's official pricing page displayed a Mounjaro list price of $1,112.16 per fill and defined a fill as four pens. NovoCare displayed an Ozempic injection list price of $1,027.51. These are manufacturer reference prices, not a forecast of what any patient will pay. [S4][S5]

We read these list prices directly from the manufacturers' official pricing pages—Lilly for Mounjaro and NovoCare for Ozempic—on the date shown; we do not use coupon sites, aggregator price trackers, or pharmacy estimates.

The official Ozempic page did not state the package quantity or supply period represented by its displayed price, so subtracting the two figures would not be a like-for-like comparison. The right comparison is the current plan-and-pharmacy result for the exact prescription—not list price alone. [S4][S5]

For a reusable estimate, the GLP-1 cost calculator can organize price inputs without claiming that an estimate is a pharmacy quote. Recheck the manufacturer's official pricing and savings pages at click time, especially because this article's price evidence is dated.

7. The better fit depends on the clinical goal

The labels create different evidence lanes. A clinician considering glycemic control may weigh the SURPASS-2 findings, but must keep the semaglutide 1 mg comparator and the trial population in view. A clinician evaluating a person with established cardiovascular disease or chronic kidney disease may also consider the additional risk-reduction indications in Ozempic's current label. Pediatric eligibility differs because Mounjaro's label includes patients age 10 and older while Ozempic's current label is for adults. [S1][S2][S3]

Coverage can dominate an otherwise reasonable clinical comparison. Before treating either option as accessible, verify whether the plan covers the exact brand for the relevant diagnosis and what documentation is required. If coverage is absent or the claim price is not sustainable, ask the clinician and plan about lawful covered alternatives rather than relying on an unverified coupon headline.

Questions to ask before choosing

1. Which current FDA-labeled indication is relevant to my diagnosis and treatment goal?
2. Do any boxed warnings, contraindications, precautions, interactions, or current medicines change the options for me?
3. How should the SURPASS-2 semaglutide 1 mg comparator affect how we interpret the results for my situation?
4. Does my plan cover the exact brand for my diagnosis, and does it require prior authorization or step therapy?
5. What will the exact prescription cost after the pharmacy runs a current claim?
6. What follow-up and monitoring does my clinician recommend?
7. If the preferred product is unavailable or unaffordable, what covered alternatives should we discuss?

Bottom line

Mounjaro and Ozempic share a weekly type 2 diabetes context, but they are not interchangeable. Tirzepatide produced larger average A1C and weight changes than semaglutide 1 mg in the bounded SURPASS-2 trial, while Ozempic's label includes additional cardiovascular and kidney-risk indications in specified adults. Mounjaro's label includes pediatric patients age 10 and older. [S1][S2][S3]

Use those differences to frame a clinician and insurance conversation—not to declare a universal winner. Verify the current labels, contraindications, exact pharmacy claim, and manufacturer terms before acting. This article is educational and does not diagnose, prescribe, determine eligibility, or replace a licensed professional.

How we keep this page current

We recheck the official Mounjaro and Ozempic list-price pages at publication and at least monthly, recheck both FDA labels before publication and whenever a new label revision appears, and re-verify manufacturer savings terms when a reader is making a decision. Labels and prices were last checked August 2, 2026.